SivoMixx - Lactic acid and bifidobacteria in high concentration
SivoMixx is a high-quality product whose production process is strictly monitored from the cultivation phase through to storage.
We are the only official distribution partner for SivoMixx in Germany. Our goods come directly from the manufacturer, checked and refrigerated. We cannot provide any warranty or advice for Sivomixx that you purchase from other sources.
Contained bacterial strains:
The following bacterial strains have been identified and registered by the Leibniz Institute German Collection of Microorganisms and Cell Cultures (DSMZ).
- S. thermophilus DSM32245
- L. acidophilus DSM32241
- L. plantarum DSM32244
- L. paracasei DSM32243
- L. helveticus DSM32242
- L. brevis DSM27961
- B. lactis DSM32246
- B. lactis DSM32247
Available in/as:
- sachets (SivoMixx 200) with 200 billion germs per sachet (30 sachets à 1.5 g/package)
- Capsules with 10 billion germs per capsule (30 pcs. à 0.24 g/pack)
- Drop with 0.2 billion germs per drop (2 vials of 5ml / pack)
Ingredients:
- Per sachet (SivoMixx 200): Mixture of 200 billion lactic acid and bifidobacteria (Slab51), maltose.
- Per capsule: Mixture of 10 billion lactic acid and bifidobacteria (Slab51), maltose. Vegetable capsule made from hydroxypropyl methylcellulose.
- Per drop (SivoMixx Drop): MCT oil, mixture of 0.2 billion lactic acid and bifidobacteria (Slab51), maltose.
Net quantity: SivoMixx 200 sachets = 45 g, SivoMixx capsules = 7.2 g, SivoMixx Drop = 10 g (10 ml)
SivoMixx is an allergen-free food supplement. Food supplements are not a substitute for a varied and balanced diet.
Manufacturer: Ormendes SA, 24 Chemin des vignettes 1008 Jouxtens-Mézery - Switzerland
By the way, there are also studies on SivoMixx in humans, dogs and cats. You can find a selection under the 'STUDIES' tab. Just have a read.
Storage and shipping instructions:
The cultures are not very sensitive to heat. Bear in mind that the cultures have their optimum ambient temperature at body temperature. Manufacturer's declaration on temperature stability.
Shipping:
From May, we will be shipping SivoMixx in a special environmentally friendly cooler bag made from recycled paper and with a cooling element. This is a precautionary measure to compensate for short-term storage above 40°C at very high outside temperatures (e.g. in delivery vehicles). In most cases, the cooling element will arrive thawed. This is desirable and keeps the temperature in the cooler bag constant. The cool bag and the cooling element increase the shipping costs by 2 euros (incl. VAT) per order. Concerns about shelf life, even with longer delivery times and higher outside temperatures, are unfounded. Due to the manufacturing process, the bags themselves are either less filled with air or often more filled with air. This is both normal. All shipping methods are suitable for SivoMixx deliveries.
Storage:
SivoMixx should be stored away from light and always in the refrigerator (2-8°C) .
- However, the pouches and drops can be stored or transported unrefrigerated for at least 7 days at temperatures up to 25°C and 2-3 days at temperatures up to 40°C without any loss of quality. We recommend storing opened sachets and drops in the refrigerator and consuming them.
- The capsules can be stored at room temperature (up to 25°C) thanks to the special and patented packaging.
Manufacturer's recommended dosage for SivoMixx-200 sachets:
- Recommended dosage per day: 1 - 2 sachets
- The recommended dosage should not be exceeded.
- The powder can simply be sprinkled or taken directly (do not heat the powder).
Manufacturer's recommended dosage for SivoMixx capsules:
- Recommended dosage per day: 1 - 4 capsules
- The recommended dosage should not be exceeded.
- Capsules can also be opened and the contents sprinkled or taken directly (do not heat the powder).
Manufacturer's recommended dosage for SivoMixx-Drop:
- Recommended dosage per day: 5 - 10 drops
- The recommended dosage should not be exceeded.
- The drops can be taken directly (do not heat the drops).
We have compiled studies here for healthcare professionals interested in the subject. The subjects of these studies were humans, but also dogs and cats.
Below you will find excerpts and entry points of these studies with SivoMixx:
-
- SLAB51 multi-strain probiotic formula increases oxygenation in oxygen-treated preterm infants. Baldassarre ME, Marazzato M, Pensa M, Loverro MT, Quercia M, Lombardi F, Schettini F, Laforgia N. Nutrients, 2023, 15: 3685
- Probiotics supplementation attenuates inflammation and oxidative stress induced by chronic sleep restriction. Zheng Y, Zhang L, Bonfili ., de Vivo L, Eleuteri AM, Bellesi M. Nutrients, 2023, 15: 1518.
- Effects of the Probiotic Mixture Slab51 (SivoMixx) as Food Supplement in Healthy Dogs: Evaluation of Fecal Microbiota, Clinical Parameters and Immune Function. Rossi G, Gioacchini G, Pengo G, Suchodolski JS, Jergens AE, Allenspach K, Gavazza A, Scarpona S, Berardi S, Galosi L, Bassotti G, Cerquetella M. Neurogastroenterol Motil, 2019, 8:e13717
- Rapid resolution of large bowel diarrhea after the administration of a combination of a high fiber diet and a probiotic mixture in 30 dogs. Rossi Giacomo, Cerquetella Matteo, Gavazza Alessandra, Galosi Livio, Berardi Sara, Mangiaterra Sara, Mari Subeide, Suchodolski Jan, Lidbury Jonathan A, Steiner Joerg M, Pengo Graziano. Vet Sci, 2020, 7:21
- Enterocolic increase of cannabinoid receptor type 1 and type 2 and clinical improvement after probiotic administration in dogs with chronic signs of colonic dysmotility without mucosal inflammatory changes. Rossi G, Gioacchini G, Pengo G, Suchodolski JS, Jergens AE, Allenspach K, Gavazza A, Scarpona S, Berardi S, Galosi L, Bassotti G, Cerquetella M. Neurogastroenterol Motil, 2019, 8:e13717
- In vitro and ex vivo evaluation of the anti-Giardia duodenalis activity of the supernatant of Slab51 (SivoMixx). Perrucci S, Fichi G, Ricci E, Galosi L, Lalle M, Rossi G. PLoS One, 2019, 7:e0213385
- Effects of a probiotic (SLAB51) on clinical and histologic variables and microbiota of cats with chronic constipation/megacolon: a pilot study. Rossi G, Jergens A, Cerquetella M, Berardi S, Di Cicco E, Bassotti G, Pengo G, Suchodolski JS. Benef Microbes, 2018, 29:101-110
